Skip to content
Bird Rock Bio
  • About Us
    • Overview
    • Our People
    • Board of Directors
  • Our Pipeline
    • Overview
    • Nimacimab
  • News
  • Careers
  • Contact
  • About Us
    • Overview
    • Our People
    • Board of Directors
  • Our Pipeline
    • Overview
    • Nimacimab
  • News
  • Careers
  • Contact

Author: Cognition Design Team

Bird Rock Bio, Inc. Gains Approval for Use of Generic Drug Name Nimacimab (RYI-018), a Monoclonal Antibody for the Treatment of NASH, Diabetic Nephropathy and Other Diseases